Biotest - Model BT595 -Primary Immune Deficiency (PID) Pipeline
IgG Next Generation is a new development of a polyvalent immungiobulin (NIG) for the treatment of immunedeficiencies and auto immune diseases. IgG Next Generation is manufactured with a new and innovative production process and will be the main product of the new manufacturing site Biotest Next Level.
Biotest has great expertise in the area of therapy with polyvalent immunoglobulins (IVIg) in primary immune deficiencies and autoimmune diseases. Building on this expertise we develop drugs for the treatment of chronic progressive diseases of the immune system.
IgG next Generation is a new development of a IVIG for the treatment of immunodeficiency and autoimmune diseases.
Biotest has been active for many years in the development and production of hyperimmunoglobulins. These are medications that are used in the treatment of chronic viral infectious diseases such as hepatitis B to prevent reinfection after organ transplantation.
